#None #Zemcelpro® #Cordex #Avanzanite

Major Partnership Announcement: Expanding Zemcelpro® in Europe

ExCellThera Inc., recognized as a front-runner in blood stem cell expansion technologies, has officially announced a significant partnership aimed at enhancing the availability of its innovative treatment, Zemcelpro® (known as dorocubicel or UM171 Cell Therapy), across Europe. This strategic collaboration has been formed with Avanzanite Bioscience B.V., granting them exclusive rights for the commercialization of Zemcelpro® in 32 countries, which encompasses the European Economic Area, the United Kingdom, and Switzerland.

Background on Zemcelpro®

Zemcelpro® is a state-of-the-art personalized cryopreserved hematopoietic stem cell transplantation product. It consists of a dual cellular component structure: UM171-expanded CD34+ cells (dorocubicel) and unexpanded CD34- cells, both sourced from a single cord blood unit. This novel therapy is specifically formulated to treat hematological malignancies such as leukemias and myelodysplastic syndromes. In the European Union, its usage is indicated for adult patients who require allogeneic hematopoietic stem cell transplantation after myeloablative conditioning and have not found suitable donor cells.

According to David Millette, CEO of Cordex, these agreements mark a pivotal moment in the journey to deliver Zemcelpro® to patients grappling with significant medical needs across Europe. Millette emphasized the strength of Avanzanite's expertise in launching treatments for rare diseases as a perfect complement to Cordex's vision for expanding patient access to this vital therapy.

Avanzanite's Role

Avanzanite is a next-generation pharmaceutical firm dedicated to making rare disease medicines more accessible throughout Europe. Co-Founder and CEO Adam Plich noted, "This partnership is aligned with our mission to ensure innovative medicines reach the patients who need them the most." He expressed enthusiasm about collaborating with Cordex to facilitate Zemcelpro®'s reach to those suffering from blood cancers where viable treatment alternatives are scarce.

Strategic Financial Framework

The licensing deal not only includes upfront payments but also encompasses development fees, milestone payments, and royalties. This arrangement creates a shared economic interest in the long-term success of Zemcelpro®, facilitating funding for a Phase 3 trial that will evaluate its efficacy and safety in high-risk acute leukemia patients and myelodysplastic syndromes.

Avanzanite is set to spearhead regulatory activities and market access, along with overseeing pricing and reimbursement, commercial operations, and the distribution of Zemcelpro® within the licensed territories. Once the regulatory transfer is completed, they will also take over the existing EU marketing authorization for the drug and plan further submissions for marketing authorization in the UK and Switzerland.

Cordex's Continuing Commitment

Meanwhile, Cordex will maintain its role in the global development of Zemcelpro® and will handle the manufacturing and supply processes to Avanzanite. The collaboration signifies both entities' commitment to advancing this crucial therapy and is a part of ongoing efforts to expedite its commercialization within the U.S. and other international territories.

Conclusion

Zemcelpro® (dorocubicel) presents an essential option for adult patients requiring allogeneic stem cell transplants, particularly when suitable donors are unavailable. The partnership between ExCellThera and Avanzanite not only highlights the importance of advancing medical treatment for hematological cancers but also demonstrates the potential of collaborative efforts in addressing unmet healthcare needs, ensuring that groundbreaking therapies are made available to those in need. This cooperation is aimed not only at bringing genuine change in the lives of patients but also at redefining the treatment landscape for blood-related malignancies in Europe.

For detailed information on this significant partnership and the innovative Zemcelpro® product, interested parties are encouraged to visit Zemcelpro.